Vicks Medinait Cold And Flu Treatment Syrup 180ml

Product details
Therapeutic indications
Vicks Medinait is used to treat cold and flu symptoms.

Dosage and method of use
Vicks Medinait should be taken in the following doses and methods:

Adults and children over 12 years: one level measuring cup (30 ml = 2 tablespoons), once a day, for no more than 3 days.
Contraindications

Known individual hypersensitivity to the components. Children under 12 years of age. Asthma, diabetes, glaucoma, prostatic hypertrophy, stenosis of the gastrointestinal and urogenital tract, epilepsy, severe liver disease or severe renal impairment. Paracetamol-based products are contraindicated in patients with manifest insufficiency of glucose-6-phosphate dehydrogenase and in those suffering from severe haemolytic anemia.
History of gastrointestinal bleeding or perforation related to previous active treatments or history of recurrent peptic ulcer / haemorrhage (two or more distinct episodes of proven ulceration or bleeding).
Severe heart failure. In case of concomitant administration with MAOIs (monoamine oxidase inhibitors) or within two weeks of taking MAOIs.
Special warnings
Seek medical advice before use if you have a cough that occurs with excessive phlegm (mucus) or a persistent cough, such as that occurs with smoking, asthma, or emphysema. High or prolonged doses of paracetamol, present in the product, can cause high-risk liver disease and even serious changes in the kidney and blood. Paracetamol should be used with caution in subjects with renal and hepatic insufficiency, including those with alcoholic cirrhotic liver disease. The dangers of overdose are greater in those with alcoholic liver disease.

Do not use with any other product containing paracetamol. The use of the product is not recommended if the patient is being treated with anti-inflammatories. During therapy with oral anticoagulants the doses should be reduced. In the rare cases of allergic reactions the administration should be suspended. Particular caution should be exercised in determining the dose in elderly subjects, in consideration of their greater sensitivity towards antihistamines. The use of antihistamines at the same time as certain ototoxic antibiotics can mask the early signs of ototoxicity, which can only reveal itself when the damage is irreversible. The product should be administered with caution in patients with cardiovascular diseases, hypertension, hyperthyroidism. Caution should be exercised in patients with a history of hypertension and / or heart failure as fluid retention and edema have been reported in association with NSAID therapy. Additive effects may occur with alcohol, hypnotics, sedatives or tranquilizers which therefore should not be taken at the same time.

The use of Vicks Medinait should be avoided concomitantly with NSAIDs, including selective COX-2 inhibitors. Undesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control the symptoms. Elderly: Elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which can be fatal.

Gastrointestinal bleeding, ulceration and perforation: Gastrointestinal bleeding, ulceration and perforation, which can be fatal, have been reported during treatment with all NSAIDs, at any time, with or without warning symptoms or a previous history of serious gastrointestinal events. In the elderly and in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation, the risk of gastrointestinal bleeding, ulceration or perforation is higher with increased doses of NSAIDs. These patients should start treatment with the lowest available dose. Concomitant use of protective agents (misoprostol or proton pump inhibitors) should be considered for these patients and also for patients taking low dose aspirin or other drugs that may increase the risk of gastrointestinal events.

Patients with a history of gastrointestinal toxicity, particularly the elderly, should report any unusual gastrointestinal symptoms (especially gastrointestinal bleeding) particularly in the initial stages of treatment. Caution should be exercised in patients taking concomitant medications that could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as aspirin. When gastrointestinal bleeding or ulceration occurs in patients taking Vicks Medinait the treatment should be discontinued. NSAIDs should be administered with caution to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as these conditions may be exacerbated (see section - side effects).

Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens – Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs. In the early stages of therapy, patients appear to be at higher risk: the onset of the reaction occurs in most cases within the first month of treatment. Vicks Medinait should be discontinued at the first appearance of skin rash, mucosal lesions or any other signs of hypersensitivity. The product contains sucrose, this should be taken into account in case of low calorie diets. After 3 days of continuous use, without noticeable results, consult your doctor. Instruct the patient to contact the physician before associating any other medication

Pregnancy and breastfeeding
Do not use during pregnancy or breastfeeding

Expiration and retention
Check the expiration date indicated on the package. The expiry date indicated on the package refers to the product in intact packaging, correctly stored.

Warning: do not use the medicine after the expiry date indicated on the package.

Composition
Vicks Medinait contains:
Active ingredient: Dextromethorphan hydrobromide 0.0500 g, Doxylamine succinate 0.0250 g, Paracetamol 2.0000 g
Excipients: propylene glycol, sodium citrate dihydrate, citric acid monohydrate, sodium benzoate, polyethylene glycol 300, sugar (sucrose), glycerin, anethole, quinoline yellow (E 104), brilliant blue FCF (E133), demineralized water.

This sheet has been prepared using information provided by the manufacturer. It should be noted that the packaging of the products is susceptible to periodic renewals by the pharmaceutical companies, therefore the photo of the product may not be updated; the only data to be trusted is the unique ministerial code (Minsan).